

# Publikationsliste

– Kurzfassung –



**Prof. Dr. med. Patrick Terheyden**

Mühlenstraße 6  
23936 Grevesmühlen

# Kurzliste Publikationen

**Terheyden P**, Sunderkötter C, Söhngen FD, Golle L, Schimo S, Baron R, Maihöfner C, Binder A, Pönisch W (2023) Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series. *Dermatol Ther (Heidelb)*. 2023 Oct;13(10):2461-2471. doi: 10.1007/s13555-023-01019-6.

Becker JC, Beer AJ, DeTemple VK, Eigentler T, Flaig MJ, Gambichler T, Grabbe S, Höller U, Klumpp B, Lang S, Pföhler C, Posch C, Prasad V, Schlattmann P, Schneider-Burrus S, Ter-Nedden J, **Terheyden P**, Thoms K, Vordermark D, Ugurel S (2023). S2k-Leitlinie - Merkelzellkarzinom - Update 2022. *J Dtsch Dermatol Ges*. 2023 Mar;21(3):305-317. doi: 10.1111/ddg.14930\_g.

Klee G, Hagelstein V, Kurzhals JK, Zillikens D, **Terheyden P**, Langan EA (2022) Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete? *Melanoma Res* 32(5):360-36.

Kurzhals JK, Klee G, Hagelstein V, Zillikens D, **Terheyden P**, Langan EA (2022) Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center *Int J Mol Sci* 23(18):10723.

da Silva IP, Ahmed T, McQuade JL; Nebhan CA, Park JJ, Versluis JM, Serra-Bellver P, Khan Y, Slattery T; Oberoi HK, Ugurel S, Haydu LE, Herbst R, Utikal J, C Pföhler, **Terheyden P**, Weichenthal M, Gutzmer R, Mohr P, Rai R, Smith JL, Scolyer RA, Arance AM, Pickering L, Larkin J, Lorigan P. Blank CU, Schadendorf D, Davies MA, Carlino MS, Johnson DB, Long GV, Lo SN, Menzies AM (2022) Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. *J Clin Oncol* 40(10):1068-1080

Spasova I, Ugurel S, Zimmer L, **Terheyden P**, Mohr A, Andtback HB, Villabona L, Leiter U, Eigentler T, Loquai C, Hassel J, Gambichler T, Haferkamp S, Mohr P, Pföhler C, Heinzerling L, Gutzmer R, Utikal J, Horny K, Schildhaus HU, Habermann D,

Hoffmann D, Schadendorf D, Becker JC (2022) Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma. *J Immunother Cancer* 10(1):e003198

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, **Terheyden P**, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Xiong H, Guezel G, Nghiem PT (2021) Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. *ESMO Open* 26;6(6):100290

Klee G, Kisch T, Kümpers C, Perner S, Schinke S, Zillikens D, Langan EA, **Terheyden P** (2021) The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis. *Rheumatol Adv Pract.* 28;5(3):rkab037

Klee G, Kurzhals J, Hagelstein V, Zillikens D, Recke A, Langan EA\*, **Terheyden P\*** (2021) Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. *Melanoma Res.*;31(5):464-471

\*geteilte Letztautorschaft

Kurzhals JK, Graf T, Boch K, Grzyska U, Frydrychowicz A, Zillikens D, **Terheyden P**, Langan EA (2021) Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. *Front Med (Lausanne)* 8:691618.

Kurzhals JK, Klee G, Busch H, Hagelstein V, Zillikens D, **Terheyden P**, Langan EA (2021) The impact of the Covid-19 pandemic on quality of life in skin cancer patients. *PLoS One* 16(8):e0255501

Kurzhals J, **Terheyden P**, Langan EA (2021) Immune checkpoint inhibition in the era of COVID-19. *Clin Exp Dermatol* 46(1):176-179

Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L, Meier F, Göppner D, Herbst RA, Zillikens D, **Terheyden P** (2021) Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. *Front Immunol* 11:588582

D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, **Terheyden P**, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Georges S, Shah P, Ellers-Lenz B, Bajars M, Güzel G, Nghiem PT (2020) Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. *J Immunother Cancer* 8(1):e000674

Langan EA, Graetz V, Allerheiligen J, Zillikens D, Rupp J, **Terheyden P** (2020) Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. *Lancet Oncol.* 21(1):e55-e65

Spasova I, Ugurel S, **Terheyden P**, Sucker A, Hassel JC, Ritter C, Kubat L, Habermann D, Farahpour F, Saeedghalati M, Peiffer L, Kumar R, Schrama D, Hoffmann D, Schadendorf D, Becker JC (2020) Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. *Clin Cancer Res.* 26(9):2257-2267

Bönisch N, Langan EA, **Terheyden P** (2019) Kutanen Angiosarkom - Radiochemotherapie mit liposomal verkapseltem pegylierten Doxorubicin. *Hautarzt.* 70(9):700-706

Corrie PG, **Terheyden P**, Ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson MLG, Goodman GR, Hsu JJ, Sadetsky N, Colburn D, Rutkowski P (2019) A prospective observational safety study of patients with BRAFV600 -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). *Br J Dermatol* 180(5):1254-1255

D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, **Terheyden P**, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M (2019) Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. *Cancer Immunol Immunother.* 68(4):609-618

Grätz V, Langan EA, Neumann A, Zillikens D, **Terheyden P** (2019) Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases. *Melanoma Res.* 29(5):516-521

Grätz V, Zillikens D, Busch H, Langan EA\*, **Terheyden P\*** (2019) Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing? *Front Med (Lausanne)* 6:257

\*geteilte Letztautorschaft

Kümpers C, Jokic M, Haase O, Offermann A, Vogel W, Grätz V, Langan EA, Perner S\*, **Terheyden P\*** (2019) Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. *Front. Med.* 6:27 **IF 2019: 3.900**

\*geteilte Letztautorschaft

Langan EA, Kümpers C, Graetz V, Perner S, Zillikens D, **Terheyden P** (2019) Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma. *Dermatol Ther.* 32(3):e12901

Kaufman HL, Russell JS, Hamid O, Bhatia S, **Terheyden P**, D'Angelo S, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P (2018) Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after  $\geq 1$  year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. *J Immunother Cancer* 19;6(1):7

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, **Terheyden P**, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hofer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM (2017) Completion Dissection vs.

Observation for Melanoma Sentinel Node Metastasis. N Engl J Med. 376(23):2211-2222

Grätz V, Lüttmann N, Haase O, Langan EA, Kemmling A, Zillikens D, **Terheyden P** (2017) Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission. Melanoma Res. 27(5):503-506 **IF 2017: 3.135**

Haase O, Angün O, Schulze F, Vogt F, Thorns C, Zillikens D, **Terheyden P** (2016) High Response Rate to Second-Line Combination Antiangiogenic chemotherapy in Patients with Metastatic Melanoma. Journal of Cancer Therapy 7, 908-918

Kaufman HL, Russell J, Hamid O, Bhatia S, **Terheyden P**, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P (2016) Avelumab, an anti-PD-L1 antibody, in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-arm, phase 2 study. Lancet Oncol.17(10):1374-1385

Lüttmann N, Grätz V, Haase O, Eckey T, Langan EA, Zillikens D, **Terheyden P** (2016) Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition. Melanoma Res. 26(5):528-31

Valentin F, Oji V, Hausser I, Liebau E, Tarinski T, Metze D, Breitzkreuz D, Traupe H, Jonca N, **Terheyden P** (2015) Increased expression of caspase-1 and IL-18 in Peeling skin disease, and a novel mutation of corneodesmosin. Acta Derm Venerol **95**:1019-1021

**Terheyden P**, Grimberg G, Hausser I, Rose C, Korge B, Krieg T, Arin M. Recessive epidermolytic hyperkeratosis caused by a novel termination codon mutation in the keratin 10 gene. J Invest Dermatol 129:2721-3

**Terheyden P**, Hofmann MA, Weiniger M, Bröcker EB, Becker JC (2007) Endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. *J Cancer Res Clin Oncol* 133:897-901

**Terheyden P**, Kortüm AK, Schulze HJ, Durani B, Remling R, Mauch C, Junghans V, Schadendorf D, Beiteke U, Jünger M, Becker JC, Bröcker EB. (2007) Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group. *J Cancer Res Clin Oncol*. 133(7):437-44

Schrama D, **Terheyden P**, Otto K, Kämmerer U, Bröcker E-B, Lühder F, Cosman D, Andersen MH, Becker JC (2006) Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells. *Eur J Immunol* 36:65-72

**Terheyden P**, Loos M, Störkel S, Kaul M (2005) Human macrophages simultaneously express membrane-C1q and Fc-receptors for IgG. *Immunol Lett* 101:202-209 **IF 2005: 2.301**

**Terheyden P**, Bröcker EB, Becker JC (2004) Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. *J Cancer Res Clin Oncol* **130**: 395-399 [Authors Reply (2005) *J Cancer Res Clin Oncol* 131:331]

**Terheyden P**, Schrama D, Pedersen LO, Andersen MH, Kämpgen E, thor-Straten P, Becker JC (2003) Longitudinal analysis of MART-1/HLA-A2 reactive T cells over the course of melanoma progression. *Scand J Immunol* 58:566-571

Becker JC, **Terheyden P**, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB (2002) Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. *Br J Cancer* 87:840-845

Schrama D, Andersen MH, **Terheyden P**, Schroder L, Pedersen LO, thor-Straten P, Becker JC (2001) Oligoclonal T-cell receptor usage of melanocyte differentiation antigen- reactive T cells in stage IV melanoma patients. *Cancer Res* 61: 493-496

**Terheyden P**, Becker JC, Kämpgen E, Bröcker EB (2000) Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma. *Melanoma Res* 10:475-482

**Terheyden P**, thor-Straten P, Bröcker EB, Kämpgen E, Becker JC (2000) CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes. *J Immunol* 164: 6633-6639

**Terheyden P**, Siedel C, Merkel A, Kämpgen E, Bröcker EB, Becker JC (1999) Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis. *J Invest Dermatol* 112: 899-902

**Terheyden P**, Kämpgen E, Rünger TM, Bröcker EB, Becker JC (1998) Immunochemotherapy of metastatic uveal melanoma with interferon alfa- 2b, interleukin-2 and fotemustine. Case reports and review of the literature. *Hautarzt* 49: 770-773



# Übersichtsartikel

Terheyden H, **Terheyden P** (2020) Tumore der Lippen und Gesichtshaut – das muss der Zahnarzt wissen! zm 110: 1310-1319

**Terheyden P**, Krackhardt A, Eigentler T (2019) The Systemic Treatment of Melanoma. Dtsch Arztebl Int. 22;116(29-30):497-504

**Terheyden P**, Mohr A, Langan EA (2019) Immuncheckpoint-Inhibition beim Merkelzellkarzinom. Hautarzt. 2019 Sep;70(9):684-690

**Terheyden P**, Dippel E (2019) Seltene Hauttumoren: Frühe Diagnose und richtige Therapie Hautarzt 70(9):660

Langan EA, Grätz V, Billmann F, Zillikens D, **Terheyden P** (2018) Does the gastrointestinal microbiome contribute to the 'obesity paradox' in melanoma survival? Br J Dermatol. 179(1):225-226

**Terheyden P**, Becker JC (2017) New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 29(3):221-226

**Terheyden P**. Neue Therapiemöglichkeiten des metastasierten Melanoms (2012) Akt Dermatol 38:243–247

**Terheyden P**, Tilgen W, Hauschild A (2008) Aktuelle Aspekte der medizinischen Versorgung des Melanoms. JDDG 6:868-882

**Terheyden P**, Bröcker E-B. Hautveränderungen bei Schilddrüsenerkrankungen (2003) JDDG 1:306-316.

Becker JC, **Terheyden P**, Bröcker EB (1997) Molecular basis of T-cell dysfunction in melanoma. Melanoma Res 7 Suppl 2:S51-S57

# Buchbeiträge

Langan E, **Terheyden P** (2022) Melanoma of the oral cavity. In: Diseases of the oral mucosa. Ed. Schmidt E.

Mohr M, **Terheyden P** (2014) Lungenmetastasen beim Melanom. In: Limmer: Lungenmetastasen, Springer, pp. 139-150

**Terheyden P**, Bröcker EB. (2010) Topisch applizierte antitumoral wirksame Medikamente – Lokale Kontaktsensibilisierung. In: Szeimies et al.: Tumoren der Haut, Georg Thieme Verlag, pp. 202-204

Eggert AAO, Otto K, McLellan AD, **Terheyden P**, Linden C, Kämpgen E, Becker JC (2006) Generation of human and murine dendritic cells. In Cell Biology: a laboratory Handbook, 3. Auflage, pp.103-112

Becker JC, **Terheyden P**, thor-Straten P. (1999) T Zell Reaktionen gegen Melanome - Rolle von CD4+ Lymphozyten. In Plettenberg A, Meigel MN, Moll I (ed.): Dermatologie an der Schwelle zum neuen Jahrtausend, pp. 479-481

**Terheyden P**, Bröcker E-B. (1999) Schilddrüse und Haut. In: Seibel MJ, Weinheimer B, Ziegler R (ed.), Schilddrüse 1999. Berlin, pp. 89-105

**Terheyden P**, Bröcker E-B, Becker JC (1997) Molekulare Mechanismen der T-Zell Dysfunktion im Falle des malignen Melanoms. In Garbe C, Rassner G, Dermatologie. Leitlinien und Qualitätssicherung für Diagnostik und Therapie, pp. 302-306

# Fallberichte

Uleer LD, Loquai C, Shimanovich I, Khandanpour C, Pruessmann JN, **Terheyden P**, Sadik D. Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab. JEADV Clin Pract. 2024;1–4.

Hübner GA, Prüßmann W, Jossifov N, Mischnik A, **Terheyden P** (2024) Complex cutaneous leishmaniasis with bone involvement. Dermatologie (Heidelb). 2024 Aug;75(8):647-652. doi: 10.1007/s00105-024-05355-2. Epub 2024 Jun 25.

Riemann S, Langan EA, **Terheyden P**, Boch K (2023) Ring-shaped plaque on the face. Skin Health Dis 26;3(5):e272.

Langan EA, Budner K, Zillikens D, **Terheyden P** (2021) Generalized morphea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report. Medicine (Baltimore) 100(16):e25513.

Neumann K, **Terheyden P**, Thaçi D (2021) Granulomatöse rosazeaartiges Exanthem unter Tofacitinib. Hautarzt 72(11):1000-1002

Klee G, von Dücker L, **Terheyden P** (2020) Anhaltende komplette Remission eines extranodalen NK/T-Zell-Lymphoms vom nasalen Typ unter Pembrolizumab und Radiotherapie. J Dtsch Dermatol Ges. 18(9):1019-1021

Mohr A, Langan EA, **Terheyden P** (2020) Sequentielle Immuncheckpoint-Inhibition beim Merkelzellkarzinom. Akt Dermatol 46: 45–49

von Dücker L, Fleischer M, Stutz N, Thieme M, Witte M, Zillikens D, Sadik CD, **Terheyden P** (2020) Primary Cutaneous Gamma-Delta T-Cell Lymphoma With Long-Term Indolent Clinical Course Initially Mimicking Lupus Erythematosus Profundus. Front Oncol. 2020 Feb 19;10:133

Sadik CD, Langan EA, Grätz V, Zillikens D, **Terheyden P** (2019) Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid. Front Immunol. 2019 Aug 14;10:1934

Sadik CD, Thieme M, Zillikens D, **Terheyden P** (2019) First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e406-e407

Lüdeke I\*, **Terheyden P\***, Grisanti S, Lücke M (2016) Entwicklung einer serösen Retinopathie unter Behandlung eines metastasierten Melanoms. Ophthalmologie. 2016 Oct;113(10):861-863

\*geteilte Erstautorschaft

Lüdeke I, **Terheyden P**, Grisanti S, Lücke M (2017) Die seröse Retinopathie: eine wichtige Nebenwirkung in der Tumorbehandlung. Ophthalmologie. 2017 Apr;114(4):378-380.

Mohr, M, Schumacher N, Zillikens D, **Terheyden P** (2017) Follikuläre und zystische Regression eines lokal fortgeschrittenen Basalzellkarzinoms nach kurzfristiger neoadjuvanter Therapie mit Vismodegib. J Dtsch Dermatol Ges.15 (10):1031-1033

Grätz V, **Terheyden P** (2016) 82-jähriger Patient mit BRAF-mutiertem metastasiertem Melanom und handhabbaren Begleitscheinungen unter Kombinationstherapie mit Cobimetinib/Vemrafenib. Thieme Case Reports 2016; 8 (9):1-16

Haase O, Angün O, Grätz V, Lüttmann N, Neumann A, Zillikens D, **Terheyden P** (2016) Response of BRAFL597Q-mutant melanoma to trametinib: Targeted melanoma therapy beyond BRAFV600 mutations [Article in German]. Hautarzt 67(8):648-52

Hoellen F, **Terheyden P**, Russ PS, Bohlmann MK. Ovarkarzinom-assoziiertes Erythema anulare centrifugum – Veränderung einer paraneoplastischen Hautveränderung nach Tumorexstirpation (2015) Der Frauenarzt 56:26

Schulze F, van Beek N, **Terheyden P**, Zillikens D, Schmidt E (2013) Concomitant bullous pemphigoid and dermatitis herpetiformis. *Dermatology* 226:217-21

**Terheyden P**, Houben R, Pajouh P, Thorns O, Zillikens D, Becker J (2010) Response to imatinib mesylate depends on the presence of the V559A mutated KIT-oncogene. *J Invest Dermatol* 130:314-6

**Terheyden P**, Kahaly G, Zillikens D, Bröcker E-B (2003) Lack of response of elephantiasic pretibial myxoedema to treatment with high-dose intravenous immunoglobulins. *Clin Exp Dermatol* 28:224-226

**Terheyden P**, Hofmann UB, Hamm H, Bröcker EB (2001) Erythroderma after corticosteroid withdrawal in papulosquamous dermatosis in children. Diagnosis: pityriasis rubra pilaris, classic juvenile type. *Hautarzt* 52:1058-1061

**Terheyden P**, Rickert S, Kämpgen E, Münnich S, Hofmann UB, Bröcker EB, Becker JC (2001) Nevus of Ota and choroid melanoma. *Hautarzt* 52:803-806

**Terheyden P**, Hornschuh B, Karl S, Becker JC, Bröcker EB (1998) Lichen planus associated with Becker's nevus. *J Am Acad Dermatol* 38:770-772